CA2093866A1 - Methodes d'inhibition de la croissance des tumeurs a resistance multiple aux anti-cancereux - Google Patents

Methodes d'inhibition de la croissance des tumeurs a resistance multiple aux anti-cancereux

Info

Publication number
CA2093866A1
CA2093866A1 CA 2093866 CA2093866A CA2093866A1 CA 2093866 A1 CA2093866 A1 CA 2093866A1 CA 2093866 CA2093866 CA 2093866 CA 2093866 A CA2093866 A CA 2093866A CA 2093866 A1 CA2093866 A1 CA 2093866A1
Authority
CA
Canada
Prior art keywords
antibody
glycoprotein
ls2h241
tumor
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2093866
Other languages
English (en)
Inventor
Lana S. Grauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of CA2093866A1 publication Critical patent/CA2093866A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA 2093866 1992-04-14 1993-04-13 Methodes d'inhibition de la croissance des tumeurs a resistance multiple aux anti-cancereux Abandoned CA2093866A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/868,983 1992-04-14
US86998392 1992-04-14

Publications (1)

Publication Number Publication Date
CA2093866A1 true CA2093866A1 (fr) 1993-10-15

Family

ID=25354556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2093866 Abandoned CA2093866A1 (fr) 1992-04-14 1993-04-13 Methodes d'inhibition de la croissance des tumeurs a resistance multiple aux anti-cancereux

Country Status (2)

Country Link
JP (1) JPH0687760A (fr)
CA (1) CA2093866A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US10201523B2 (en) 2013-09-13 2019-02-12 Western University Of Health Sciences Use of wilforlide A for overcoming chemotherapy resistance

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5698178A (en) * 1994-08-05 1997-12-16 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US6468530B1 (en) 1994-08-05 2002-10-22 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US7067128B2 (en) 1994-08-05 2006-06-27 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US10201523B2 (en) 2013-09-13 2019-02-12 Western University Of Health Sciences Use of wilforlide A for overcoming chemotherapy resistance

Also Published As

Publication number Publication date
JPH0687760A (ja) 1994-03-29

Similar Documents

Publication Publication Date Title
EP0805871B1 (fr) Anticorps anti-cd30 prevenant le clivage proteolytique et la liberation de l'antigene cd30 membranaire
EP1713830B1 (fr) Immunoglobulines anti-epcam
CA2081150C (fr) Utilisation de preparations contenant des anticorps pour l'immunosuppression
Shen et al. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG.
JP4854912B2 (ja) 癌に対する抗体
US20110020332A1 (en) Prevention of tumors with monoclonal antibodies against neu
WO1994022478A1 (fr) PREVENTION DE TUMEURS AVEC DES ANTICORPS MONOCLONAUX DIRIGES CONTRE L'ONCOGENE $i(NEU)
US20110165599A1 (en) Monoclonal antibody therapy for pancreas cancer
EP0938505A1 (fr) Anticorps monoclonaux anti-endogline et leur utilisation en therapie antiangiogenique
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
WO2008033495A2 (fr) Méthode de détection et de traitement de troubles cutanés
EP0569141A2 (fr) Inhibition de la croissance des tumeurs multirésistantes aux médicaments à l'aide d'anticorps
TWI846095B (zh) 抗cd47-cldn18.2雙特異性抗體及其用途
CN115943162A (zh) 抗Claudin18.2抗体以及其用途
CN113631582A (zh) 一种融合蛋白及其用途
JPH05213775A (ja) Ｂｆａ抗体
CA2093866A1 (fr) Methodes d'inhibition de la croissance des tumeurs a resistance multiple aux anti-cancereux
US5639621A (en) Monoclonal antibodies against tumor-associated antigens
Stevenson et al. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells
JPH05117165A (ja) 抗癌剤
AT500651A1 (de) Immuntherapie für rektalen krebs
CN117430711A (zh) 用于治疗肝细胞性肝癌的双特异性融合蛋白及其应用
CN116261590A (zh) 抗cd3抗体以及其用途
CN113015751A (zh) 一种融合蛋白及其用途
US20100119514A1 (en) Antibodies Against Cancer

Legal Events

Date Code Title Description
FZDE Dead